Literature DB >> 1849324

Results of surgical treatment in patients with stage IIIA non-small-cell lung cancer.

Y Watanabe1, J Shimizu, M Oda, Y Hayashi, S Watanabe, T Iwa.   

Abstract

From 1973 to 1989, surgical resection was performed in 235 stage IIIA non-small-cell lung cancer patients (78% of all admitted stage IIIA patients). Complete resection was accomplished in 155 patients and 80 underwent incomplete resection. The rate of incomplete resection was higher in patients with adenocarcinoma than in those with squamous cell carcinoma. There were 7 operative deaths (2.8%) among the patients undergoing operation. The five-year survival rate of the group having complete resection was 32%, whereas that of the incomplete resection group was 5% (p less than 0.05). The five-year survival rate of T3NO-1MO patients with complete resection was 50% and that of T1-2N2MO patients was 30%. However, the five-year survival rate of patients with T3N2MO disease was significantly poorer at 10% (p less than 0.05). The five-year survival rates of patients undergoing complete resection including the combined resection of an adjacent organ were: pericardium 43%; chest wall 43%; pleura 34%; and bronchus 46%. Forty-nine patients survived over three years and 10 of them died between three and five years after surgery, but five-year, four-year, and three-year survivors numbered 29, 4, and 6, respectively. Surgical resection appears to be the treatment of choice for stage IIIA non-small-cell lung cancer whenever complete resection is feasible.

Entities:  

Mesh:

Year:  1991        PMID: 1849324     DOI: 10.1055/s-2007-1013929

Source DB:  PubMed          Journal:  Thorac Cardiovasc Surg        ISSN: 0171-6425            Impact factor:   1.827


  6 in total

1.  The practice of cardiothoracic surgeons in the perioperative staging of non-small cell lung cancer.

Authors:  P Goldstraw
Journal:  Thorax       Date:  1992-01       Impact factor: 9.139

2.  Surgery on unfavourable persistent N2/N3 non-small-cell lung cancer after trimodal therapy: do the results justify the risk?

Authors:  Volker Steger; Tobias Walker; Migdat Mustafi; Karoline Lehrach; Thomas Kyriss; Stefanie Veit; Godehard Friedel; Thorsten Walles
Journal:  Interact Cardiovasc Thorac Surg       Date:  2012-09-20

3.  Chest wall resection and reconstruction for lung cancer: surgical techniques and example of integrated multimodality approach.

Authors:  Mauro Loi; Antonio Mazzella; Isacco Desideri; Ludovic Fournel; Emelyne Canny Hamelin; Philippe Icard; Antonio Bobbio; Marco Alifano
Journal:  J Thorac Dis       Date:  2020-01       Impact factor: 2.895

Review 4.  Mind-mapping for lung cancer: towards a personalized therapeutics approach.

Authors:  N Mollberg; M Surati; C Demchuk; R Fathi; A K Salama; A N Husain; T Hensing; R Salgia
Journal:  Adv Ther       Date:  2011-02-09       Impact factor: 3.845

Review 5.  Surgical management of lung cancer.

Authors:  Adam Lackey; Jessica S Donington
Journal:  Semin Intervent Radiol       Date:  2013-06       Impact factor: 1.513

6.  Prognostic Factor and Clinical Outcome in Stage III Non-Small Cell Lung Cancer: A Study Based on Real-World Clinical Data in the Korean Population.

Authors:  Ho Cheol Kim; Wonjun Ji; Jae Cheol Lee; Hyeong Ryul Kim; Si Yeol Song; Chang-Min Choi
Journal:  Cancer Res Treat       Date:  2021-02-16       Impact factor: 4.679

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.